Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer

Cancer Research

Volumn 50, Issue 13, 1990, Pages 4087-4091

  Berchuck, A ^a,d   Whitaker, R ^a   Olt, G ^a   Soper, J T ^a   Clarke Pearson, D L ^a   Kamel, A ^a,e   Bast, R C ^a,b   Kerns, B ^a   Kinney, R ^a   Dodge, R ^a   Marks, P ^c   McKenzie, S ^c   Yin, S ^c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE CANCER INSTITUTE   (United States)

^c Siemens Healthcare Diagnostics Inc   (United States)

^d Medical Center   (United States)

^e AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; FEMALE; GENE EXPRESSION; HISTOCHEMISTRY; HISTOLOGY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; ONCOGENE NEU; OVARY CARCINOMA; PRIORITY JOURNAL; SURVIVAL;

FEMALE; HUMAN; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PROBABILITY; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RECEPTOR, ERBB-2; REOPERATION; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0025281906     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Bargmann, C. L., Hung, M. C., and Weinberg, R. A. The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature (Lond.), 5/9: 226–229, 1986.
2. Schechter, A. L., Stern, D. F., Vaidyanathan, L., Decker, S. J., Drebin, J. A., Greene, M. I., and Weinberg, R. A. The neu oncogene: an α-β-related gene encoding a 185,000-M tumour antigen. Nature (Lond.), 312: 513–516, 1984.
3. Kokai, Y., Cohen, J. A., Drebin, J. A., and Greene, M. I. Stage- and tissue-specific expression of the neu oncogene in rat development. Proc. Natl. Acad. Sei. USA, 84: 8498–8501, 1987.
4. Padhy, L. C., Shih, C., Cowing, D., Finkelstein, R., and Weinberg, R. A. Identification of a phosphoprotein specifically induced by the transforming DNA of rat neuroblastomas. Cell, 28: 865–871, 1982.
5. Bargmann, C. I., Hung, M. C., and Weinberg, R. A. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of pl85. Cell, 45: 649–657, 1986.
6. Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., and McGuire, W. L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (Wash. DC), 235: 177–182, 1987.
7. Van De Viver, M. J., Peterse, J. L., Mooi, W. J., Wisman, P., Lomans, J., Dilesio, O., and Nüsse, R. neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N. Engl. J. Med., 319: 1239–1245, 1988.
8. Venter, D. J., Tuzi, N. I., Kumar, S., and Gullick, W. J. Overexpression of the c-erbB-2 oncoprotein in human breast carcinomas: immunohistological assessment correlates with gene amplification. Lancet, 2: 69–72, 1987.
9. Barnes, D. M., Lammie, G. A., Millis, R. R., Gullick, W. L., Allen, D. S., and Altman, D. G. An immunohistochemical evaluation of c-erbB-2 expression in human carcinoma. Br. J. Cancer, 58: 448–452, 1988.
10. Wright, C., Angus, B., Nicholson, S., Sainsbury, R. C., Cairns, J., Gullick, W. J., Kelly, P., Harris, A. L., and Wilson Home, C. H. Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res., 49: 2087–2090, 1989.
11. Tyson, F. L., Soper, J. T., Daly, L., Fowler, W. C., Jr., Haskill, J. S., Kraus, M. H., and Bast, R. C., Jr. Overexpression and amplification of the c-erbB-2 (HER2/neu) proto-oncogene in epithelial ovarian tumors and cell lines. Proc. Am. Assoc. Cancer Res., 29: 471, 1988.
12. Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., and Press, M. F. Studies of HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (Wash. DC), 244: 707–712, 1989.
13. McKenzie, S. J., Marks, P. J., Lam, T., Morgan, J., Panicali, D. L., Trimpe, K. L., and Carney, U. P. Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, pi85. Oncogene, 4: 543–548, 1989.
14. Annual Report on the Treatment of Gynecologic Cancer. In: H. L. Kottmeier (ed.), International Federation of Gynecologists and Obstetricians, Stockholm, Sweden, Vol, 17, 1979.
15. Serov, S. F., and Scully, R. E. Histological typing of ovarian tumors. In: International Histological Classification of Tumors, No. 9. Geneva: World Health Organization, 1973.
16. Kaplan, E. L., and Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53: 457–481, 1958.
17. Mantel, N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother. Rep., 50: 163–170, 1966.
18. Ishitoya, J., Toriyama, M., Oguchi, N., Kitamura, K., Ohshima, M., Asano, K., and Yamamoto, T. Gene amplification and overexpression of EGF receptor in squamous cell carcinomas of the head and neck. Br. J. Cancer, 59: 559–562, 1989.
19. Sainsbury, J. R., Farndon, J. R., Needham, G. K., Malcom, A. J., and Harris, A. L. Epidermal growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet, 1: 1398–1402, 1987.
20. Berchuck, A., Soisson, A. P., Olt, G. J., Soper, J. T., Clarke-Pearson, D. L., Bast, R. C., Jr., and McCarty, K. S., Jr. Epidermal growth factor receptor expression in normal and malignant endometrium. Am. J. Obstet. Gynecol., 767: 1247–1252, 1989.
21. Tal, M., Wetzler, M., Josefberg, Z., Deutch, A., Gutman, M., Assaf, D., Kris, F., Shiloh, Y., Givol, D., and Schlessinger, J. Sporadic amplification of the HER2/neu protooncogene in adenocarcinomas of various tissues. Cancer Res., 48: 1517–1520, 1988.
22. Lacroix, H., Iglehart, J. D., Skinner, M. A., and Kraus, M. H. Overexpression of erbB-2 or EGF receptor proteins present in early stage mammary carcinoma is detected simultaneously in matched primary tumors and regional metastases. Oncogene, 4: 145–151, 1989.
23. Bacus, S., Flowers, J. L., Press, M. F., Bacus, J. W., and McCarty, K. S., Jr. The evaluation of estrogen receptor in primary breast carcinoma by computer-assisted image analysis. Am. J. Clin. Pathol., 90: 233–243, 1988.
24. Di Fiore, P. P., Pierce, J. H., Kraus, M. H., Segatto, O., King, C. R., and Aaronson, S. A. erbB-2 is a potent oncogene when overexpressed in NIH/ 3T3 cells. Science (Wash. DC), 237: 178–182, 1987.
25. Drebin, J. A., Link, V. C., Stern, D. F., Weinberg, R. A., and Greene, M. I. Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell, 41: 695–706, 1985.